Narayana Hrudayalaya Ltd.

rs,

ecretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code –539551(EQ), 975516 & 976418 Dear Sir/Madam, To, The

86 billion

centers)  Owned by Bridgepoint, one of the world’s leading private market growth investors with $86 billion in assets under management Acquisition Overview  Acquired 100% of Practice Plus Group Hospitals

100%

rket growth investors with $86 billion in assets under management Acquisition Overview  Acquired 100% of Practice Plus Group Hospitals Limited – 5th largest private healthcare network in the UK  Focus

183 million

day care procedures an excellent platform for growth Valuation and Financing  Acquired for ~GBP 183 million* implying 9.2x FY25E EV/EBITDA multiple on currently operational centers  Target growing at 12% Y-

9.2x

n excellent platform for growth Valuation and Financing  Acquired for ~GBP 183 million* implying 9.2x FY25E EV/EBITDA multiple on currently operational centers  Target growing at 12% Y-o-Y over last 5

12%

illion* implying 9.2x FY25E EV/EBITDA multiple on currently operational centers  Target growing at 12% Y-o-Y over last 5Y  Leverage financing: ~GBP 150 million financed through long term debt with teno

150 million

currently operational centers  Target growing at 12% Y-o-Y over last 5Y  Leverage financing: ~GBP 150 million financed through long term debt with tenor of 7 years Transaction Structure & Timelines  No pre

99%

t length 10 Hospitals & Surgical Centers Latent demand 4- 6 weeks Waiting time for surgeries 99% Recommended by patients All facilities rated by CQC as “Good” or “Outstanding” ~700k+ Cases

229 million

k+ Cases attended to in FY25 Theatre ARPC : £ 2,075 Non-Theatre ARPC : £ 130 Revenue FY24 : £ 229 million FY25E : £ 250 million 5Y Growth Revenue : 12% CAGR Centre EBITDA : 12.5% CAGR 6 Revenue Mix of

250 million

in FY25 Theatre ARPC : £ 2,075 Non-Theatre ARPC : £ 130 Revenue FY24 : £ 229 million FY25E : £ 250 million 5Y Growth Revenue : 12% CAGR Centre EBITDA : 12.5% CAGR 6 Revenue Mix of Practice Plus Group Ho

12.5%

Revenue FY24 : £ 229 million FY25E : £ 250 million 5Y Growth Revenue : 12% CAGR Centre EBITDA : 12.5% CAGR 6 Revenue Mix of Practice Plus Group Hospitals Limited Revenue Split Therapy Mix Private-

7%

R 6 Revenue Mix of Practice Plus Group Hospitals Limited Revenue Split Therapy Mix Private-Pay 7% Others 6% UTC 5% Volume Split Private-Pay 1% NHS 93% NHS 99% OPD 13% Diagnostics 6% Endosc

“EBITDA FY23A FY24A FY25* 211 32 13 229 38 16 250 43 20 GBP Mn Net Block Net working capital Less - Other non current liab.”

“Net Worth FY23 FY24 FY25* 63 (2) (52) 9 78 (0) (67) 11 83 6 (65) 24”

Note

2

Asset Light model with growth visibility

1

Asset Light model with growth visibility

• Asset light day care model, focused on high throughput indications with • Asset light day care model, focused on high throughput indications with propensity for private pay and large NHS waiting times propensity for private pay and large NHS waiting times • Clear revenue visibility and margins • Clear revenue visibility and margins • Existing centres with ~50% capacity for future growth • Existing centres with ~50% capacity for future growth Patient Growth Digital Integration Clinical Excellence • Relocate & upgrade existing centers to • Leverage NH’s Athma platform and attract private patients • Enhance service offerings broader digital capabilities to improve patient outcomes and retention • Best-in-class clinical practices • Leverage NH's clinical capabilities to expand the range of services offered Market Reach • • Improvement in private payer contracting and relationships Increased efforts in private patient acquisition Operational Efficiency • Management has a proven track reco

Note

• Financial Year from 1st Oct to 30th Sept • Centre EBITDA and Adj. EBITDA excludes losses from the new centre at Birmingham which is currently not fully operational • Birmingham started in FY25 and has an operating loss of GBP 6.1 Mn* for FY25 *as per Management Accounts shared - in line with outturn analysis conducted from 9mFY25 diligence financials **excludes inter-company balances, Goodwill adjustment from PPG Holdings as those are not part of the transaction perimeter 9 Appendix: Valuation Summary Valuation summary GBP Mn Enterprise Value EV/(FY25- TTM Adj. EBITDA) EV/(FY26- NTM Adj. EBITDA)